Biochemical studies further confirmed that IGF2BPs, including IGF2BP2, stabilize m6A-modified RNAs across various cellular, physiological, and pathological settings, including human cancer cells such as hepatocellular carcinoma (HepG2), cervical cancer (HeLa), prostate cancer (22Rv1), and acute myeloid leukemia. Here, IGF2BP2 is linked to cancer.